Combining bortezomib with R-CHOP in the treatment of recurrent non-GCB DLBCL is better than that of GCB DLBCL, and can improve the prognosis of non-GCB DLBCL [51]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.